IV Ketamine vs. Spravato (Esketamine)
A detailed comparison of the two most common forms of clinical ketamine therapy: IV infusion and Spravato nasal spray.
Reviewed for clinical accuracy against peer-reviewed literature and FDA guidelines · Last updated April 2026
Key Takeaway
IV ketamine and Spravato (esketamine) are both effective treatments for treatment-resistant depression, but they differ in FDA approval status, cost structure, and insurance coverage. Spravato is FDA-approved and often covered by insurance but requires treatment at a certified REMS facility. IV ketamine is off-label, costs $400–$800 per session out-of-pocket, and can be administered at any licensed clinic. Response rates are comparable at 60–70% for TRD.
Side-by-Side Comparison
| Factor | IV Ketamine Infusion | Spravato (Esketamine) |
|---|---|---|
| Drug | Racemic ketamine (R + S enantiomers) | Esketamine (S-enantiomer only) |
| FDA Status | Off-label for psychiatric use | FDA-approved (TRD 2019, suicidal ideation 2020) |
| Route | Intravenous infusion (40–60 min) | Nasal spray (self-administered under supervision) |
| Dose | 0.5 mg/kg over 40 min | 56 mg or 84 mg |
| Bioavailability | 100% | ~48% |
| Cost per Session | $400–$800 | $590–$885 (list price) |
| Insurance Coverage | Rarely covered (off-label) | Often covered with prior authorization |
| Initial Protocol | 6 infusions over 2–3 weeks | Twice weekly for 4 weeks, then taper |
| Maintenance | Every 3–6 weeks as needed | Weekly or every 2 weeks |
| Monitoring Time | 30–60 min post-infusion | 2 hours (REMS requirement) |
| Provider Requirement | Any licensed clinic with monitoring capabilities | REMS-certified facility only (3,302+ locations) |
| Approved Conditions | Off-label: TRD, PTSD, anxiety, chronic pain, OCD, suicidal ideation | TRD, MDD with suicidal ideation |
| Response Rate (TRD) | 60–70% | 50–70% |
| Onset of Action | Hours to days | Hours to days (full effect by week 4) |
| Driving Restriction | No driving day of treatment | No driving rest of day (REMS mandate) |
Cost Comparison: What Will You Pay?
IV Ketamine: Full Out-of-Pocket
Since IV ketamine is used off-label, patients pay the full cost themselves in most cases:
- Initial 6-infusion series: $2,400–$4,800
- Maintenance (8–16 infusions/year): $3,200–$12,800/year
- First-year total estimate: $5,600–$17,600
Many clinics offer package pricing, payment plans, and accept HSA/FSA funds. Some offer sliding-scale pricing.
Spravato: Insurance Often Covers
Spravato’s FDA approval status makes insurance coverage possible, significantly reducing out-of-pocket costs:
- With Janssen Savings Program: $0 copay (eligible commercial insurance patients)
- With insurance (no savings program): Varies by plan; copays range from $30–$300+ per session
- Without insurance: $590–$885 per session
- Prior authorization: Almost always required; must document failure of 2+ antidepressants
Bottom line: If your insurance covers Spravato, it will likely be the more affordable option despite the higher list price. If you are paying entirely out-of-pocket or your condition is not TRD/suicidal ideation, IV ketamine provides more flexibility in dosing and broader off-label indications.
Effectiveness: What Does the Evidence Say?
Both treatments show strong antidepressant efficacy, but the evidence base differs:
IV Ketamine
The evidence base spans over 20 years of research, including the landmark Zarate et al. 2006 trial and subsequent replication studies. The 2013 two-site randomized controlled trial by Murrough et al. found a 64% response rate at 24 hours after a single infusion in patients with TRD. However, most studies are relatively small (20–70 patients) and short-term.
Spravato
Spravato’s FDA approval is based on Phase 3 clinical trials (TRANSFORM-1, TRANSFORM-2, SUSTAIN-1) involving over 1,700 patients — a larger evidence base than any individual IV ketamine study. TRANSFORM-2 demonstrated statistically significant improvement in MADRS scores at 4 weeks compared to placebo nasal spray plus a new oral antidepressant.
Key Difference: Racemic vs. S-Enantiomer
IV ketamine is racemic — it contains both the S-enantiomer and R-enantiomer. Some researchers hypothesize that the R-enantiomer contributes distinct neurobiological effects that may enhance antidepressant outcomes. However, direct head-to-head randomized controlled trials comparing racemic IV ketamine to Spravato remain limited, making definitive efficacy comparisons difficult.
Frequently Asked Questions
Is Spravato or IV ketamine more effective for depression?
Both show response rates of approximately 60–70% for treatment-resistant depression. Direct head-to-head trials are limited. Some clinicians prefer IV ketamine because racemic ketamine contains both S- and R-enantiomers, while Spravato has the most rigorous Phase 3 data. The best choice depends on your insurance coverage, specific diagnosis, and provider availability.
Does insurance cover IV ketamine or Spravato?
Spravato is FDA-approved and often covered by insurance with prior authorization. IV ketamine is off-label and rarely covered. Most patients pay $400–$800 per IV session out of pocket. The Janssen Savings Program can reduce Spravato copays to $0 for eligible patients.
Can I switch from IV ketamine to Spravato or vice versa?
Yes. Some patients start with IV ketamine for faster initial response, then transition to Spravato for maintenance if insurance covers it. Others try Spravato first and switch to IV if response is inadequate. Your psychiatrist will guide the transition and adjust dosing.
Which is faster: IV ketamine or Spravato?
Both can produce noticeable mood improvement within hours to days. IV ketamine has 100% bioavailability with effects often felt during the infusion, while Spravato (48% bioavailability) may take slightly longer to reach peak plasma levels. For full clinical response, Spravato trials measured outcomes at 4 weeks.
Can Spravato treat conditions other than depression?
Spravato is FDA-approved only for TRD and MDD with suicidal ideation. IV ketamine is used off-label for a broader range of conditions including PTSD, anxiety, chronic pain, and OCD. If your primary condition is not TRD, IV ketamine offers more clinical flexibility.
Find IV Ketamine or Spravato Providers
Compare 3,606 clinics offering IV ketamine and 3,302 Spravato-certified centers.
Browse All Clinics →References
- Zarate CA Jr, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry. 2006;63(8):856–864.
- Murrough JW, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. American Journal of Psychiatry. 2013;170(10):1134–1142.
- U.S. Food and Drug Administration. FDA approves new nasal spray medication for treatment-resistant depression. March 5, 2019.
- Popova V, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study (TRANSFORM-2). American Journal of Psychiatry. 2019;176(6):428–438.
- Wajs E, et al. Esketamine nasal spray plus oral antidepressant: long-term safety (SUSTAIN-2). Journal of Clinical Psychiatry. 2020;81(3):19m12891.
- DrugsRegistry.com. Provider data compiled from Spravato REMS registry and ASKP directory, April 2026. https://drugsregistry.com/about/